Monograph Details
|
|
Dermatological Disorders
> Miscellaneous dermatological conditions
|
|
VANIQA |
| Manufacturer |
|
SkinMedica, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hair growth retardant. |
| Generic Name |
|
Eflornithine HCl 13.9%; crm. |
| Indications |
|
Reduction of unwanted facial hair in women. |
| Children |
|
Not recommended. |
| Adults |
|
Apply a thin layer to affected areas of face and adjacent areas under the chin twice daily at least 8 hours apart; rub in thoroughly. Do not wash treated area for at least 4 hours. Continue to use hair removal techniques as needed. May apply cosmetics or sunscreens after cream dries. |
| Precautions |
|
Reduce frequency if irritation or intolerance develops; discontinue if irritation continues. Abraded or broken skin. Pregnancy (Cat.C): not recommended. Nursing mothers. |
| Adverse Reactions |
|
Acne, pseudofolliculitis barbae, stinging, headache, burning, dry skin, erythema, tingling, dyspepsia, irritation, rash, alopecia, dizziness. |
| How Supplied |
|
Crm—30g, 60g (2x30g) |
|
|
|
|
